BL-IPI to support risk stratification and targeted novel treatment approaches for Burkitt lymphoma

Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma. BL is curable for most...

Is CD47 a good target for immunotherapy in lymphoma?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Steven Horwitz, Memorial Sloan...

ZUMA-12: Is CAR T-cell therapy effective in high-risk DLBCL as first-line therapy?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Sattva...

Liso-cel updates from TRANSCEND-CLL-004 and TRANCEND-NHL-001 trials

Lisocabtagene maraleucel (liso-cel), is an investigational, CD19-directed, defined composition, 4-1BB chimeric antigen receptor...

Satellite Symposium | Patient with R/R CLL—Latin American perspective

The virtual Lymphoma Hub Satellite Symposium, at the European School of Haematology (ESH) ‘2nd How to Diagnose and Treat:...

Satellite Symposium | Patient with R/R CLL—European perspective

The virtual Lymphoma Hub Satellite Symposium, at this year's European School of Haematology (ESH) ‘2nd How to Diagnose and Treat:...

Satellite Symposium | Patient with R/R DLBCL—European perspective

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a...

Satellite Symposium | Patient with R/R DLBCL—US perspective

At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub was proud to host...

Educational theme: The role of ctDNA in lymphoma management

This article is the first in an educational series exploring the role of circulating tumor DNA in the management of patients with lymphoma.

Does ctDNA add value to current prognostic markers for identifying high-risk patients?

This is the third episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual...

Umbralisib and ublituximab combination is superior to current standard of care for patients with untreated, relapsed, or refractory CLL

The synergistic activity of umbralisib, a dual inhibitor of...

Does polatuzumab vedotin, venetoclax, and rituximab combined enhance tumor responses in R/R DLBCL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub...